



Ethanol Extract of Perillae Herba Enhances Pentobarbital-Induced Sleep and Non-Rapid Eye Movement (NREM) Sleep through GABA_A-ergic Systems

Yeong Ok Kwon, Tae-Woo Ha, and Ki-Wan Oh*

College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea

Abstract – Perillae Herba has been traditionally used for the sedation in the oriental countries. Therefore, this study was conducted to determine whether Perillae Herba ethanol extract (PHEE) enhances pentobarbital-induced sleeping behaviors in animals. In addition, the possible mechanisms are demonstrated. PHEE (12.5, 25 and 50 mg/kg, p.o.) reduced the locomotor activity in mice. PHEE reduced sleep latency and augmented the total sleep time in pentobarbital (42 mg/kg, i.p.)-induced sleep in mice. Furthermore, the number of sleeping mice treated with sub-hypnotic pentobarbital (28 mg/kg, i.p.) increased. PHEE (50 mg/kg, p.o.) decreased the sleep/wake cycles and wakefulness, and increased total sleeping time and NREM sleep in electroencephalogram (EEG) of rats. In addition, PHEE (0.1, 1.0 and 10 µg/ml) increased the intracellular Cl⁻ level through the GABA receptors in the hypothalamus of rats. Moreover, the protein of glutamate decarboxylase (GAD) was overexpressed by PHEE. It was found that PHEE enhanced pentobarbital-induced sleeping behaviors through GABA_A-ergic transmissions.

Keywords – Perillae Herba ethanol extract (PHEE), Pentobarbital-induced sleep, Glutamic acid decarboxylase (GAD), GABA, GABA_A receptors, Electroencephalogram (EEG)

Introduction

The stressed life in modern society causes peoples sleep disorder more seriously. The sleep helps physical and mental states to be healthy because it occupies more than a third of life. So, fatigue, tiredness, drowsiness, decline of immunization, deterioration of interpersonal relations and depression are closely related when not taken enough sleep.¹⁻⁴ The sleep is achieved through the γ -aminobutyric acid (GABA)-ergic systems in the central nervous system (CNS). In CNS, glutamic acid decarboxylase (GAD) converts glutamate (the excitatory neurotransmitter) into GABA (the inhibitory neurotransmitter). GABA neurons, glutamate neurons and astrocytes are adjacent.⁵ If the GABA-ergic systems are activated by binding GABA to GABA_A receptors, the extracellular Cl⁻ will move into the cells to create a hyperpolarized state.⁵ As a result, it induces sleep state. Subunits of GABA_A receptors are differently acted in accordance with the substance because GABA_A receptors is composed of α , β , γ , δ , ϵ , θ and π subunits.⁶⁻⁷

Generally, various medicines such as benzodiazepines

and barbiturates have been used to treat the sleep disorder or insomnia. However, these medicines have many the side-effects. To avoid the side-effects, the studies using natural plants are ongoing. Of these plants, Perillae Herba is the leaf of *Perilla frutescens*, a yearly plant, belonged to *Dicotyledonlamiaceae*. It has purple color and strong fragrance in general. Perillae Herba has been well cultivated in East Asia including China and Korea. It has been used as medicines such as a folk remedy for sedation.⁸ According to a recent study, Honda (1986) simply reported that Perillae Herba has the effect on sedation, and extends the sleep induced by hexobarbital⁹. Essential oils of Perillae Herba are also able to change the hippocampal expression of brain-derived neurotrophic factor.¹⁰ Rosmarinic acid, a constituent of Perillae Herba, showed the antidepressant effect and sedative effect on some levels when carrying out the swimming test after injecting it to depressed mice¹¹ and, made the rigid behaviors become sedative when administered to mice exposed to stress.¹² Therefore, this study was performed to know whether Perillae Herba ethanol extract (PHEE) improve pentobarbital-induced sleep in changing electroencephalogram (EEG) through GABA_A-ergic systems.

*Author for correspondence

Ki-Wan Oh, College of Pharmacy, Chungbuk National University, Cheongju 361-763, Republic of Korea.
Tel: +82-43-261-2827; E-mail: kiwan@chungbuk.ac.kr

Experimental

Plants and extracts preparation – Perillae Herba was purchased from Lim-Agricultural Products Market (Yeongcheon, Korea). This plant was confirmed by professor Mi-kyung Lee who works at the laboratory of pharmacognosy department in Chungbuk National University. Dried PerillaeHerba 1.0 kg was extracted with 50% ethanol at room temperature. It was concentrated under a constant pressure to obtain crude extract. Extract was concentrated under pressure to yield crude extract which was centrifuged and filtered, the filtrate was concentrated under a vacuum using a rotary evaporator to yield (10%) dried powder (100 g).

Reagents and chemicals – Sodium pentobarbital (100 mg/2 ml) were purchased through Hanlim Pharm. Co., Ltd. (Seoul, Korea), and Diazepam (10 mg/2 ml) were purchased through and Samjin Pharm. (Seoul, Korea). Muscimol (Tocris Bioscience, Bristol, UK) was purchased and Dimethyl sulfoxide (Amresco Solon, Ohio, USA) was purchased. Fetal bovine serum (FBS), Dulbecco's Modified Eagle Medium (DMEM), Trypsin-EDTA and Penicilline-Streptomycin was purchased from GIBCO (Grand island, NY, USA). N-(ethoxycarbonyl methyl)-6-methyl quinolinium bromide (MQAE) and Cytosine beta-d-arabinofuranoside was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Specific polyclonal antibodies on the GABA_A receptors subunits of the GAD_{65/67} extracted from rabbits and anti-rabbit immunoglobulin G-horseradish peroxidase was purchased from Abcam Inc. (Cambridge, UK). Chemiluminescent HRP substrate was purchased from Millipore Corporation (Billerica, MA, USA).

Animals – ICR mice and Sprague Dawley (SD) rats was purchased from Samtako (Osan, Korea). Rodents were kept in acrylic cages of 45 × 60 × 23 cm. The water and feed were given to rodents sufficiently. Temperature and humidity has been maintained 22 ± 2 °C and 50 - 52%, respectively, and the animal-room to change light and darkness automatically was used. Rodents went adapted during one week prior to the experiment. The experiment was performed between 10:00 a.m. and 5:00 p.m. complying with National Institute of Health Guide for Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1985) and the Animal Care and Use Guidelines of Chungbuk National University.

Measurement of locomotor activity – Locomotor activity was measured using a tilting type ambulometer (O'Hara AMB-10 in Tokio in Japan). PHEE (12.5, 25 and 50 mg/kg) and diazepam (2.0 mg/kg) were administered

orally to the mice, 1 h and 30 min prior to the experiment, respectively. Each mouse was adjusted 10 min prior to the experiment in the activity cage that is 20 cm of diameter, 18 cm of height (Park *et al.*, 2005). After oral administration of PHEE and diazepam, locomotor activity was measured for 1 h¹³.

Pentobarbital-induced sleep – Mice (10 - 15) were used in a group. Fasting was conducted 24 hs before the test, and the experiment was carried out between 10:00a.m. and 5:00 p.m. Pentobarbital sodium and muscimol was dissolved in 0.9% saline. PHEE (12.5, 25, 50 mg/kg) was orally administrated 1 h before measurement, and muscimol (0.2 mg/kg) was orally administrated 30 min before measurement. Then, mice that do not appear stereotactic reflection were moved to another empty cage after pentobarbital sodium (42 mg/kg) was injected intraperitoneally (0.1 ml/10 g). The period from the administration of pentobarbital sodium to not showing stereotactic reflection was recorded as sleep latency, and the period from falling into the sleep to showing stereotactic reflection was recorded as total sleeping time. When mice treated with pentobarbital sodium did not sleep within 15 minutes, those animals were excluded from the experiment.¹⁴

Measurement of electroencephalogram – After i.p. injection of pentobarbital (50 mg/kg) into the abdominal cavity of rats, they were anesthetized. The hair on rat's head was removed by hair trimmer. Rat placed on a pad that has a fixed stereotaxic apparatus. The scalp was made an incision with a scalpel and splayed the portion of incision under that scalp. Then, a transmitter (Data Sciences International TA11CTA-F40, MN, USA) was inserted, and the two lines of the seven lines which were connected to transmitter was fixed under the skin. The periosteum to see skull was removed, and the blood was wiped with a sterile cotton. The two holes were made in the skull with a drill (A: 2.0 [Bregma], L: 1.5; P: 7.0 [Bregma], L: 1.5 contra-lateral), and two lines except lines fixed under the skin was fixed to the skull using the dental cement. After incision regions were sutured with silk 4 - 0 suture, antibiotics (5 million unit potassium penicillin-G Injection, Kunwha, Korea) was injected into the abdominal cavity.

Following 7 days post-surgical recovery, PHEE (50 mg/kg) was administrated one hour before the experiment. EEG measurements were a little changed from the previous study.¹⁵ Cage where rat is was put on a measuring device. Set of EEG signals were amplified, and designated as 0.5 - 20.0 Hz range. -0.5 / +0.5 Volts per units x2 was set to add, and it was controlled by Data Sciences

International analog converter. The measuring signal was changed into a sampling rate of 128 HZ through AD converter (Eagle PC30, USA), transferred to the computer, and saved. On-line fast fourier transformation (FFT) collected the EEG data every two seconds following processing the Hanning window. It was created a power density values from 0.0 to 20.0 by FFT analyzer. FFT data calculated the average in the range from 0 to 20 Hz per 10 seconds. The sleep data and FFT result are stored every 10 seconds for additional analysis. Movement of the rats was associated with the remote receiver formed transistor-transistor logic (TTL) pulses, which was considered as a measure of the movement. Data measurements were conducted between 11:00 a.m. and 5:00 p.m., and each rat was measured at the same time. Sleep data were stored through the Sleep-Sign 2.1 software (KISSEI Comtec Co. Ltd., Matsumoto, Japan). Data have been classified as wakefulness, non-rapid eye movement (NREM) and rapid eye movement (REM) every 10 seconds¹⁶. Software classified the EEG signal based on the next. Wakefulness and NREM were classified as a high frequency and slow wave respectively. During REM sleep, δ wave (0.75~4.0 Hz) of EEG was reduced, and the θ wave (5.0~9.0 Hz, 7.5 Hz at the peak) increased. Sleep/wake cycles and sleeping time of NREM, REM and total sleep time (NREM + REM) is measured for 6 hours. The absolute EEG power recorded wakefulness, NREM and REM in a box of 0.5 Hz in the range of from 0.5 to 20 Hz for 6 hours. NREM, REM and wakefulness were calculated in δ , θ , α (8.0~13.0 Hz). Values measured were calculated in Microsoft Excel.

Primary cell culture – The primary culture was conducted using hypothalamus of 8 days-old SD rats.¹⁷ The bottom of 96 well microplate was coated with Poly-L-lysine (50 $\mu\text{g}/\text{ml}$). 1.0×10^5 cells/ml cells were put into each well of 96 well microplate. Cells were cultured using 10% heat-inactivated fetal bovine serum (FBS), 2.0 mM glutamine, 100 $\mu\text{g}/\text{ml}$ gentamycin, 10 $\mu\text{g}/\text{ml}$ antibiotic-antimycotic solution (Sigma), 25 mM potassium chloride and DMEM. Cells was cultured at the proper humidity, 5% CO_2 and 37 °C incubator. 16 hours after the incubation, cytosine arabinofuranoside (final concentration: 10 μM ; Sigma) was treated. Then, Neurobasal A medium was used instead of DMEM.

Measurement of intracellular Cl^- influx – The intracellular Cl^- influx was measured in hypothalamic cells by using MQAE that is the Cl^- sensitive fluorescence probe.¹⁸ After treated with 10 μM MQAE (final concentration) were incubated overnight, cells were washed using the pH 7.4 buffer including 10 mM HEPES,

2.4 mM HPO_4^{2-} , 0.6 mM H_2PO_4^- , 10 mM D-glucose and 1 mM MgSO_4 three times. After PHEE (0.1, 1.0 and 10 $\mu\text{g}/\text{ml}$) was treated respectively in each well, fluorescence was measured in the excitation wavelength 320 nm and emission wavelength 460 nm using the microplate reader (SpectraMax M2e Multi-mode, PA, USA).¹⁹ F/F_0 value was calculated using F value which is measured in sample-group and F_0 value which is measured in control-group.

Western blot of $\text{GAD}_{65/67}$ and GABA_A receptors subunit – PHEE (12.5, 25 and 50 mg/kg) were orally administered 1 h before experiment and diazepam (2.0 mg/kg) were orally injected 30 min before experiment in the mice. After sample-processing, The hypothalamus of mice was homogenized with 4 °C lysis buffer (25 mM Tris-HCl/pH 7.4, 150 mM NaCl, 1 mM CaCl_2 , 1% Triton X-100, 1 mM PMSF, 10 $\mu\text{l}/\text{ml}$ aprotinin, 1 mM NaF and 2 mM sodium ortho-vanadate). Then, it was centrifuged for 15 min at 4 °C, 13,000 rpm, and the supernatant was collected. Bradford protein assay method was used to calculate protein concentration²⁰. The calculated protein was put in 10% SDS-polyacrylamide gel. And, it was electrophoresed. Proteins in gel were transferred by using the PVDF membrane (Hybond-P GE Healthcare, Amersham, UK). The membrane transferred was blocked for one hour and at room temperature by using the 5% (w/v) BSA dissolved in the Tris buffered saline solution including 0.1% Tween-20. The membrane was washed with TBST solution including 3% Tween-20 three times. The specific polyclonal antibody for the GABA_A receptors and $\text{GAD}_{65/67}$ was diluted in 1:2,500 and made with 5.0% BSA and TBST. After it was attached to the membrane, it was incubated overnight at 4 °C. After washing membrane with PBS three times, the membrane adding horseradish peroxidase-conjugated secondary antibody (1:3000 for goat anti-rabbit IgG) made of TBST was incubated for 4 hours at room temperature. After washing with TBST three times, Proteins in membrane were taken using ECL solution (Roche Diagnostics, Mannheim, Germany).

Statistical analysis – All statistical analysis was conducted with SigmaStat software of SPSS Inc. (Chicago, USA). Results are shown as mean \pm SEM. When compared to the control group and the sample group, Significance was evaluated by Analysis of Variance (ANOVA). If there is a significant difference, values were compared respectively with Dunnett-test. However, in sub-hypnotic pentobarbital-induced sleep, the number of sleeping mice was compared by using Chi-square test. It was considered that *P* value has considerable significance when less than 0.05.

Result and Discussion

Decreased locomotor activity by PHEE. After PHEE (12.5, 25 and 50 mg/kg, p.o.) were administered, the locomotor activity was measured (Fig. 1). In comparison with control group, PHEE (25 mg/kg) reduced about 29.3% and PHEE (50 mg/kg) reduced about 40.8%. Particularly, the diazepam (2 mg/kg) group used as a positive control, reduced about 70.4%.

Enhanced pentobarbital-induced sleep by PHEE. PHEE (12.5, 25 and 50 mg/kg, p.o.) and muscimol (0.2 mg/kg, p.o.) were administered prior to medicating pentobarbital (42 mg/kg, i.p.). As a result, sleep latency was decreased and total sleep time was increased. In sleep latency (Fig. 2.A), PHEE (25 mg/kg) decreased approximately 12.8%, and PHEE (50 mg/kg) decreased approximately 19.9%. In total sleep time (Fig. 2.B), PHEE (50 mg/kg) increased approximately 29.3%. Muscimol (0.2 mg/kg, p.o.) as a positive control, decreased approximately 30.8% in sleep latency, and increased approximately 37.9% in total sleep time.




Fig. 1. Effects of PHEE and diazepam (DZ) on locomotor activity test in mice. DZ and PHEE were orally administrated, respectively 30 min and 1 hour before the testing. The measurement of ambulation activity was carried out for 1 hour. Each bar represents the mean with the mean \pm S.E.M. The significance was evaluated by using Dunnetttest. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, compared to the control (CONT).

Improved sub-hypnotic pentobarbital-induced sleep by PHEE. Sub-hypnotic pentobarbital (28 mg/kg, i.p.) was injected following PHEE (12.5, 25 and 50 mg/kg, p.o.) and muscimol (0.2 mg/kg, p.o.). The more concentration of PHEE was thick, the more counts of mice falling the sleep were increased (Table 1). Mostly, significant increase




Fig. 2. Effects of muscimol (MUSC) and PHEE on onset and duration of sleep in mice treated with pentobarbital. Mice were starved from 24 hours prior to the experiment. Before pentobarbital injection, muscimol and PHEE were treated by i.p. respectively. (A) The sleep latency and (B) Total sleeping time were measured. Each bar represents the mean \pm S.E.M. The significance was evaluated by using Dunnett-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, compared to the control (CONT).

Table 1. Effects of muscimol and PHEE on the number of falling sleep and sleep time in mice treated with sub-hypnotic dose of pentobarbital (28 mg/kg, i.p.)

Group	Dose (mg/kg)	No. falling asleep/total	Sleep time (min)
Control	0	8/15	30.0 \pm 3.7
Muscimol	0.2	15/15**	49.8 \pm 2.8***
PHEE	12.5	8/10	39.9 \pm 5.1
	25	9/10	43.1 \pm 3.0*
	50	10/10*	48.9 \pm 1.8***

The significance was evaluated by Chi square test and Dunnett test ($n = 10 - 15$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, compared to control.




Fig. 3. Effects of PHEE (50 mg/kg) on counts of sleep-wake cycles in rats. Each bar represents the mean ± S.E.M. The significance was evaluated by using Dunnet test. *** $P < 0.005$, compared to the control (CONT).




Fig. 4. Effects of PHEE on sleep architectures in rats. It was separated the wakefulness and sleep (NREM and REM) state. Each bar represents the mean ± S.E.M. The significance was evaluated by using Dunnet test. ** $P < 0.01$, compared to the control.

was showed in PHEE (50 mg/kg) and muscimol (0.2 mg/kg). The sleep time of mice falling the sleep was increased. PHEE (25 mg/kg), PHEE (50 mg/kg) increased roughly 43.7%, 63%, respectively and muscimol (0.2 mg/kg) also increased roughly 66% compared with control.

Reduced sleep/wake cycles by PHEE. As a result measuring electroencephalogram after PHEE (50 mg/kg, p.o.) was administered in rats, the counts of sleep/wake cycles was reduced (Fig. 3). In comparison with control, PHEE (50 mg/kg) reduced about 33.6% and showed significant change.

Changed sleep architectures by PHEE. Sleep architectures of rats medicating PHEE (50 mg/kg, p.o.) were changed (Fig. 4). PHEE (50 mg/kg) decreased approximately 57.5% in wakefulness time but increased approximately 6.7% in total sleep time. That is, PHEE (50 mg/kg) group fell a longer sleep than sleeping time of control group. However, there are not significant alteration on




Fig. 5. Effects of PHEE on EEG power density of wakefulness (A), REM sleep (B) and NREM sleep (C). The power density was divided with delta-wave, theta-wave and alpha-wave. Each bar represents the mean ± S.E.M. The significance was evaluated by using Dunnet test. * $P < 0.05$, compared to the control.

NREM sleep and REM sleep.

Altered power density by PHEE. Power density of δ , θ , α -waves of wakefulness, REM sleep and NREM sleep was measured through EEG of rats. Wakefulness and REM sleep did not have significant changes (Fig. 5A, Fig. 5B). However, NREM sleep was changed (Fig. 5C). In




Fig. 6. Effects of pentobarbital and PHEE on Cl⁻ influx in primary cultured hypothalamic neuron cells. The hypothalamic neuron cells were cultured for 8 days, and then Cl⁻ influx of the cells was incubated with MQAE. After pentobarbital (PENT, 10 μM) and PHEE (0.1, 1 and 10 μg/ml) were treated for 1 hour, the measurement was carried out. Each bar represents the mean ± S.E.M. The significance was evaluated by using *Dunnett t-test*. ****P* < 0.005, compared to the control (CONT).

waves of NREM sleep, α-wave was decreased roughly 18.1% although there were not changes in δ and θ-waves.

Increased intracellular Cl⁻ influx in primary cultured hypothalamic cells by PHEE. When PHEE (0.1, 1 and 10 μg/ml) were treated in primary cultured hypothalamic cells, influx of Cl⁻ was measured. The more concentration rises, the more Cl⁻ influx was increased (Fig. 6). PHEE (1 μM) increased about 43.4% and PHEE (10 μM) increased about 69.76%. Particularly, pentobarbital (10 μM) as a positive control increased about 74.18%. PHEE (1, 10 μM) and pentobarbital (10 μM) showed significant changes.

Over-expressed GAD_{65/67} by PHEE. Expression of GAD_{65/67} was measured after PHEE (12.5 and 25 mg/kg) was injected in mice. Both PHEE (12.5 mg/kg) and PHEE (25 mg/kg) changed the expression of GAD_{65/67}, (Fig. 7). PHEE (12.5 mg/kg) enhanced approximately 43.5% and PHEE (25 mg/kg) enhanced approximately 54.9% compared with control.

Over-expressed GABA_A receptors subunits by PHEE. Of GABA_A receptors subunits, expression of α₃, α₄, α₅, β₁, β₂ and γ₃ subunits was measured following PHEE (50 mg/kg) was administered in mice. Changes were in α₃, α₅, β₁, β₂ and γ₃ subunits except α₄ subunit (Fig. 8). In comparison with control, PHEE (50 mg/kg) improved 78.9%, 46.7%, 35.4%, 60% and 70.1% in α₃, α₅, β₁, β₂ and γ₃ subunits respectively. Diazepam (2 mg/kg) which is a positive control improved 74.8%, 23.1% and 36.4% in α₃, β₁ and γ₃ subunits respectively.

Perilla herba has been used to relax from old times in




Fig. 7. Effects of PHEE on the expression of GAD. After PHEE (12.5 and 24 mg/kg) oral administration, the expression of GAD was measured with the expression of GAPDH. GAPDH was needed equally to compare with the expression of the proteins. Each bar represents the mean ± S.E.M. The significance was evaluated by using *Dunnett test*. **P* < 0.05, ***P* < 0.01, compared to the control (CONT).




Fig. 8. Effects of PHEE on the expression of GABA_A receptors subunits. After PHEE (50 mg/kg) oral administration, the expression of GABA_A receptors subunits was measured with the expression of GAPDH. GAPDH was needed equally to compare with the expression of the proteins. Each bar represents the mean ± S.E.M. The significance was evaluated by using *Dunnett test*. **P* < 0.05, ***P* < 0.01, ****P* < 0.005, compared to the control.

the oriental countries. According to the recent study, Parilla herba consists of various materials including perillaldehyde,

limonene, cyanin, shisonin, rosmarinic acid, adenine and arginine.²¹ Perillaldehyde showed antidepressant-like effects, which related to GABA-ergic systems, on the olfactory nervous system in mice.²² Rosmarinic acid revealed sedative effects on some levels when carrying out the swimming test after injecting it to depressed mice¹¹ and when administered to mice exposed to stress.¹² Adenine, a type of bases, becomes adenosine after combining with deoxyribose. Adenosine receptors modulate GABA_A receptor-mediated responses.²³ Because the sleep disorders are associated with sedative action and GABA_A-ergic systems, this study was performed to identify whether *PerillaeHerba* is useful on insomnia.

We first carried out the measurement of locomotor activity in mice administrating *PerillaeHerba* ethanol extract (PHEE). The result presented the locomotor activity was more reduced in the higher concentration. Through this, we knew PHEE has sedative effects. After injecting hypnotic pentobarbital (42 mg/kg, i.p.), PHEE increased the total sleep and decreased the sleep latency in mice. Also, after injecting sub-hypnotic pentobarbital (28 mg/kg, i.p.), PHEE increased the counts of mice falling the sleep as well as the total sleep. Because pentobarbital is one of the barbiturates, it combines with GABA_A receptor which has the barbiturate binding site. GABA_A receptor combining with pentobarbital is activated and finally causes results such as the inducing sleep in CNS.²⁴ So, we found PHEE has ability improving the pentobarbital-induced sleep. In measurement of electroencephalogram (EEG) administrating PHEE (50 mg/kg, p.o.) in rats, PHEE decreased the sleep/wake cycles, which are regulated by hypothalamus.²⁵ In addition, the sleep architectures were changed. Waking time decreased and total sleeping time increased. The α -wave of non-rapid eye movement (NREM) sleep was reduced in power density. Falling asleep is to become states of rapid eye movement (REM) sleep and NREM sleep. Entering into NREM sleep is to fall the deep sleep. While sleeping, REM sleep and NREM sleep are repeated and, density of sleep-waves such as α , θ , δ -waves is changed.²⁵ According to previous studies, not only the extension of NREM and REM sleep but also increase of slow waves in NREM sleep plays important roles in the sleep. GABA_A receptor agonists decrease the wakefulness and increase REM and NREM sleep²⁶. GABA_A receptor agonists include materials such as benzodiazepines and barbiturates. That is, PHEE improved the sleep as GABA_A receptor agonists.

To check whether PHEE influence GABA_A-ergic systems, intracellular influx of Cl⁻ as well as the protein expressions of GAD_{65/67} and GABA_A receptors subunits

was measured in hypothalamus. PHEE enhanced intracellular Cl⁻ influx. When GABA_A receptor agonists bind to the binding sites, Cl⁻ channels of GABA_A receptors open. The cells are hyperpolarized when Cl⁻ enters into these through opened Cl⁻ channels. Hyperpolarized cells are able to induce sedation and sleep. The protein expressions of GAD_{65/67} and GABA_A receptors subunits were changed. PHEE increased expressions of GAD_{65/67} which changes glutamate into GABA as an enzyme. Also, α_3 , α_5 , β_1 , β_2 and γ_3 subunits were overexpressed except α_4 subunit in GABA_A receptors subunits. GABA_A receptors have diverse subunits and these assemble another in various forms.²⁷⁻²⁸ Most existing subunits-compound of GABA_A receptors is closely connection with hypnotics and sedation²⁹. So, it was recognized that PHEE related to GABA_A-ergic mechanisms. To sum up, PHEE decreased the locomotor activity. PHEE improved hypnotic/sub-hypnotic pentobarbital-induced sleep and the sleep/wake cycles, sleep architectures (wakefulness and total sleep) and power density of NREM. In addition, PHEE increased intracellular Cl⁻ influx as well as the protein expressions of GAD_{65/67} and GABA_A receptors subunits. It suggests that somnogenic effects of PHEE may be mediated by GABA_A-ergic systems and PHEE would be effective on the treatment of insomnia.

Acknowledgments

This study was supported by a research grant of Chungbuk National University in 2015.

References

- (1) Pilcher, J. J.; Ginter, D. R.; Sadowsky, B. J. *Psychosom. Res.* **1997**, *42*, 583-596.
- (2) Doi, Y.; Minowa, M.; Tango, T. *Sleep.* **2003**, *26*, 467-471.
- (3) Iliescu, E. A.; Coo, H.; McMurray, M. H. *Nephrol. Dial. Transplant.* **2003**, *18*, 126-132.
- (4) Phillips, K. D.; Sowell, R. L.; Boyd, M.; Dudgeon, W. D.; Hand, G. A.; Mind-Body Research Group. *Qual. Life Res.* **2005**, *14*, 959-170.
- (5) Joanna, M. W.; Stachowicz, K.; Nowak, G.; Pilc, A. The Loss of Glutamate-GABA Harmony in Anxiety Disorders; InTech: USA, **2011**, p 24.
- (6) Olsen, R. W.; Sieghart, W. *Pharmacol. Rev.* **2008**, *60*, 243-260.
- (7) Whiting, P. J. *Drug Discov. Today* **2003**, *8*, 445-450.
- (8) Ahn, H. *Korean J. Food Preserv.* **2006**, *13*, 703-707.
- (9) Honda, G.; Koezuka, Y.; Tabata, M. *Chem. Pharm. Bull.* **1988**, *36*, 3153-3155.
- (10) Yi, L. T.; Li, J.; Geng et, D. J. *Ethnopharmacol.* **2013**, *147*, 245-253
- (11) Takeda, H.; Tsuji, M.; Inazu, M.; Egashira, T.; Matsumiya, T. *Eur. J. Pharmacol.* **2002**, *449*, 261-267.
- (12) Takeda, H.; Tsuji, M.; Miyamoto, J.; Matsumiya, T. *Psychopharmacology (Berl)* **2002**, *164*, 233-235.

- (13) Morton, G. J.; Kaiyala, K. J.; Fisher, J. D.; Ogimoto, K.; Schwartz, M. W.; Wisse, B. E. *Am. J. Physiol. Endocrinol. Metab.* **2011**, *300*, 392-401.
- (14) Wolfman, C.; Viola, H.; Marder, M.; Wasowski, C.; Ardenghi, P.; Izquierdo, I.; Paladini, A. C.; Medina, J. H. *Eur. J. Pharmacol.* **1996**, *318*, 23-30.
- (15) Sanford, L. D.; Yang, L.; Liu, X.; Tang, X. *Brain Res.* **2006**, *1084*, 80-88.
- (16) Tokunaga, S.; Takeda, Y.; Niimoto, T.; Nishida, N.; Kubo, T.; Ohno, T.; Matsuura, Y.; Kawahara, Y.; Shinomiya, K.; Kamei, C. *Biol. Pharm. Bull.* **2007**, *30*, 363-366.
- (17) Ma, Y.; Han, H.; Eun, J. S.; Kim, H. C.; Hong, J. T.; Oh, K. W. *Biol. Pharm. Bull.* **2007**, *30*, 1748-1753.
- (18) West, M. R.; Molloy, C. R. *Anal. Biochem.* **1996**, *241*, 51-58.
- (19) Wagner, C.; Vargas, A. P.; Roos, D. H.; Morel, A. F.; Farina, M.; Nogueira, C. W.; Aschner, M.; Rocha, J. B. *Arch. Toxicol.* **2010**, *84*, 89-97.
- (20) Fanger, B. O. *Anal. Biochem.* **1987**, *162*, 11-17.
- (21) Igarashi, M. Miyazaki, Y. *Evid. Based Complement. Alternat. Med.* **2013**, *2013*, 1-7.
- (22) Ito, N.; Nagai, T.; Oikawa, T.; Yamada, H.; Hanawa, T. *Evid. Based Complement. Alternat. Med.* **2011**, *2011*, 1-5.
- (23) Hu, H. Z.; Li, Z. W. *J. Physiol.* **1997**, *501 (Pt 1)*, 67-75.
- (24) Möhler, H. *J. Recept. Signal Transduct. Res.* **2006**, *26*, 731-740.
- (25) Miller, M. A. *Front. Neurol.* **2015**, *6*, 1-9.
- (26) Liu, Z.; Xu, X. H.; Liu, T. Y.; Hong, Z. Y.; Urade, Y.; Huang, Z. L.; Qu, W. M. *CNS Neurosci. Ther.* **2012**, *18*, 623-630.
- (27) Mehta, A. K.; Ticku, M. K. *Brain Res. Brain Res. Rev.* **1999**, *29*, 196-217.
- (28) Lambert, J. J.; Belelli, D.; Harney, S. C.; Peters, J. A.; Frenguelli, B. G. *Brain Res. Brain Res. Rev.* **2001**, *37*, 68-80.
- (29) Choi, J. J.; Kim, Y. S.; Kwon, Y. O.; Yoo, J. H.; Chong, M. S.; Lee, M. K.; Hong, J. T.; Oh, K. W. *Nat. Prod. Sci.* **2015**, *21*, 219-225.

Received November 10, 2016

Revised January 12, 2017

Accepted January 12, 2017